Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa

systematic syntheses, meta-analyses, and meta-regressions

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We aimed to investigate hepatitis C virus (HCV) epidemiology among hemodialysis (HD) patients in the Middle East and North Africa (MENA). Our data source was an HCV biological measures database populated through systematic literature searches. Descriptive epidemiologic syntheses, effects meta-analyses and meta-regressions, and genotype analyses were conducted. We analyzed 289 studies, including 106 463 HD patients. HCV incidence ranged between 0 and 100% as seroconversion risk, and between 0 and 14·7 per 1000 person-years as incidence rate. The regional pooled mean estimate was 29·2% (95% CI: 25·6–32·8%) for HCV antibody positive prevalence and 63·0% (95% CI: 55·4–70·3%) for the viremic rate. Region within MENA, country income group, and year of data collection were associated with HCV prevalence; year of data collection adjusted odds ratio was 0·92 (95% CI: 0·90–0·95). Genotype diversity varied across countries with four genotypes documented regionally: genotype 1 (39·3%), genotype 2 (5·7%), genotype 3 (29·6%), and genotype 4 (25·4%). Our findings showed that one-third of HD patients are HCV antibody positive and one-fifth are chronic carriers and can transmit the infection. However, HCV prevalence is declining. In context of growing HD patient population and increasing HCV treatment availability, it is critical to improve standards of infection control in dialysis and expand treatment coverage.

Original languageEnglish
Pages (from-to)1-21
Number of pages21
JournalEpidemiology and Infection
DOIs
Publication statusAccepted/In press - 9 Oct 2017

Fingerprint

Northern Africa
Eastern Africa
Middle East
Hepacivirus
Renal Dialysis
Meta-Analysis
Epidemiology
Genotype
Hepatitis C Antibodies
Information Storage and Retrieval
Incidence
Infection Control
Dialysis
Odds Ratio
Regression Analysis
Databases
Therapeutics
Infection
Population

Keywords

  • Epidemiology
  • hemodialysis
  • hepatitis C
  • Middle East and North Africa
  • prevalence

ASJC Scopus subject areas

  • Epidemiology
  • Infectious Diseases

Cite this

@article{f68ac7736166439dab922412a7faf5d7,
title = "Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta-regressions",
abstract = "We aimed to investigate hepatitis C virus (HCV) epidemiology among hemodialysis (HD) patients in the Middle East and North Africa (MENA). Our data source was an HCV biological measures database populated through systematic literature searches. Descriptive epidemiologic syntheses, effects meta-analyses and meta-regressions, and genotype analyses were conducted. We analyzed 289 studies, including 106 463 HD patients. HCV incidence ranged between 0 and 100{\%} as seroconversion risk, and between 0 and 14·7 per 1000 person-years as incidence rate. The regional pooled mean estimate was 29·2{\%} (95{\%} CI: 25·6–32·8{\%}) for HCV antibody positive prevalence and 63·0{\%} (95{\%} CI: 55·4–70·3{\%}) for the viremic rate. Region within MENA, country income group, and year of data collection were associated with HCV prevalence; year of data collection adjusted odds ratio was 0·92 (95{\%} CI: 0·90–0·95). Genotype diversity varied across countries with four genotypes documented regionally: genotype 1 (39·3{\%}), genotype 2 (5·7{\%}), genotype 3 (29·6{\%}), and genotype 4 (25·4{\%}). Our findings showed that one-third of HD patients are HCV antibody positive and one-fifth are chronic carriers and can transmit the infection. However, HCV prevalence is declining. In context of growing HD patient population and increasing HCV treatment availability, it is critical to improve standards of infection control in dialysis and expand treatment coverage.",
keywords = "Epidemiology, hemodialysis, hepatitis C, Middle East and North Africa, prevalence",
author = "Harfouche Manale and Hiam Chemaitelly and Sarwat Mahmud and K. CHAABNA and Silva Kouyoumjian and {Al Kanaani}, Zeinab and Laith Aburaddad",
year = "2017",
month = "10",
day = "9",
doi = "10.1017/S0950268817002242",
language = "English",
pages = "1--21",
journal = "Epidemiology and Infection",
issn = "0950-2688",
publisher = "Cambridge University Press",

}

TY - JOUR

T1 - Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa

T2 - systematic syntheses, meta-analyses, and meta-regressions

AU - Manale, Harfouche

AU - Chemaitelly, Hiam

AU - Mahmud, Sarwat

AU - CHAABNA, K.

AU - Kouyoumjian, Silva

AU - Al Kanaani, Zeinab

AU - Aburaddad, Laith

PY - 2017/10/9

Y1 - 2017/10/9

N2 - We aimed to investigate hepatitis C virus (HCV) epidemiology among hemodialysis (HD) patients in the Middle East and North Africa (MENA). Our data source was an HCV biological measures database populated through systematic literature searches. Descriptive epidemiologic syntheses, effects meta-analyses and meta-regressions, and genotype analyses were conducted. We analyzed 289 studies, including 106 463 HD patients. HCV incidence ranged between 0 and 100% as seroconversion risk, and between 0 and 14·7 per 1000 person-years as incidence rate. The regional pooled mean estimate was 29·2% (95% CI: 25·6–32·8%) for HCV antibody positive prevalence and 63·0% (95% CI: 55·4–70·3%) for the viremic rate. Region within MENA, country income group, and year of data collection were associated with HCV prevalence; year of data collection adjusted odds ratio was 0·92 (95% CI: 0·90–0·95). Genotype diversity varied across countries with four genotypes documented regionally: genotype 1 (39·3%), genotype 2 (5·7%), genotype 3 (29·6%), and genotype 4 (25·4%). Our findings showed that one-third of HD patients are HCV antibody positive and one-fifth are chronic carriers and can transmit the infection. However, HCV prevalence is declining. In context of growing HD patient population and increasing HCV treatment availability, it is critical to improve standards of infection control in dialysis and expand treatment coverage.

AB - We aimed to investigate hepatitis C virus (HCV) epidemiology among hemodialysis (HD) patients in the Middle East and North Africa (MENA). Our data source was an HCV biological measures database populated through systematic literature searches. Descriptive epidemiologic syntheses, effects meta-analyses and meta-regressions, and genotype analyses were conducted. We analyzed 289 studies, including 106 463 HD patients. HCV incidence ranged between 0 and 100% as seroconversion risk, and between 0 and 14·7 per 1000 person-years as incidence rate. The regional pooled mean estimate was 29·2% (95% CI: 25·6–32·8%) for HCV antibody positive prevalence and 63·0% (95% CI: 55·4–70·3%) for the viremic rate. Region within MENA, country income group, and year of data collection were associated with HCV prevalence; year of data collection adjusted odds ratio was 0·92 (95% CI: 0·90–0·95). Genotype diversity varied across countries with four genotypes documented regionally: genotype 1 (39·3%), genotype 2 (5·7%), genotype 3 (29·6%), and genotype 4 (25·4%). Our findings showed that one-third of HD patients are HCV antibody positive and one-fifth are chronic carriers and can transmit the infection. However, HCV prevalence is declining. In context of growing HD patient population and increasing HCV treatment availability, it is critical to improve standards of infection control in dialysis and expand treatment coverage.

KW - Epidemiology

KW - hemodialysis

KW - hepatitis C

KW - Middle East and North Africa

KW - prevalence

UR - http://www.scopus.com/inward/record.url?scp=85030837569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030837569&partnerID=8YFLogxK

U2 - 10.1017/S0950268817002242

DO - 10.1017/S0950268817002242

M3 - Article

SP - 1

EP - 21

JO - Epidemiology and Infection

JF - Epidemiology and Infection

SN - 0950-2688

ER -